[GenscriptUSA]

A recent study in Science Translational Medicine* describes the development and testing of a potential new therapeutic for treating obesity and diabetes. The therapeutic peptide (which was playfully termed "Twincretin"), was engineered by combining sequences from the incretin peptide hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The resulting peptide was subsequently engineered with a PEGylation modification to enhance pharmacokinetics.


Need PEGylated peptides for incretin therapeutics or other peptide-based diabetes/obesity drug candidates? Try GenScript's peptide synthesis service.


GLP-1 has previously been the focus of incretin therapies, due to its ability to suppress appetite, which results in weight loss, and its agonistic effect on the GLP-1 receptor which leads to increased β cell (cells that secrete insulin) survival and proliferation. Overexpression of GIP has been shown to improve body weight and glycemic control. Administration of the twincretin peptide resulted in weight loss in mice and was shown to be more effective than treatment with either peptide alone. In additional experiments, the insulinotropic effect of the twincretin peptide in mice was shown to be translatable to monkeys and humans.

[sale0303]

This study had begun from United State where researchers observed the practical over Mice and many other animals. University of Florida conducted this research and produced a pray which was speedily losing the weight of animals. The university researcher hold the view that the role of Pepetite GP-1 lasts incretin effects on the subject due to greater stimulation effects over insulin secretion. It controls reduction of food intake, regulation of postprandial glucagon, slow gastric emptying, and enhancement to glucose dependence. This treatment has been centered on augmenting the availability of insulin in the body. Either directly administration of insulin or through the oral mechanism which is responsible for insulin secretion. These mechanisms do not result in hypoglycemia. Besides, Researchers of University of Copenhagen tried to determine the effects of glucagon peptide 1 receptor (GLP-1R) for weight loss. After thoroughly studying the matter while investigating cholesterol, liver enzyme levels, blood sugar and blood pressure, they concluded that if its doze is over taken, it may result in side effects. The patients who were researched during the process had side effects of vomiting, diarrhea, and nausea.
On the other hand, these researchers hold the view that additional benefits can also be achieved through GLP-1 like reduction in cholesterol level and blood pressure. Not only this, they also opine that when GLP-1 is given to obese patients without or with diabetes, it may result in clinically beneficial effects over the body weight. Professor Raj Padwal of University of Alberta writes the same remarks as stated by the researchers of Copenhagen. But he discloses an uncertainty over the safety of GLP-1 agonist. The research over Glp-1 is still in process in different universities and researchers are trying to identify the possible and temporal effects which may have some hidden and drastic impacts. But, it is right in saying that it has the ability to reduce the weight immediately and abruptly.